| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BMS-345541 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.009 | 0.8 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.8 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | -0.009 | 0.8 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |